Ascentage Pharma Reports 2025 Interim Financials

TL;DR

Ascentage Pharma dropped its 2025 interim results, check the 6-K for the deets.

AI Summary

Ascentage Pharma Group International reported its unaudited six-month financial results for the interim period ending August 20, 2025. The company, based in Suzhou, China, filed a Form 6-K to furnish a press release detailing these results and business updates. This filing is made under the 1934 Securities Exchange Act.

Why It Matters

This filing provides investors with a mid-year update on Ascentage Pharma's financial performance and operational progress, crucial for assessing the company's trajectory.

Risk Assessment

Risk Level: low — This is a routine financial results disclosure (6-K) and does not contain new material events or significant strategic shifts.

Key Players & Entities

• Ascentage Pharma Group International (company) — Registrant
• August 20, 2025 (date) — Date of press release
• August 2025 (date) — Reporting period for Form 6-K
• Suzhou, Jiangsu, China (location) — Company's principal executive offices

FAQ

Key Financial Figures

• $0.0001 — 22 million ordinary shares, par value US$0.0001 per share, of the Company at a price of
• $190.1 million — ately HKD1,492 million (approximately US$190.1 million based on an exchange rate of 1 USD to 7
• $600,000 — dered and approved the payment of up to $600,000 in interest payments to those Indemnifi

Filing Documents

• ea0254141-6k_ascentage.htm (6-K) — 15KB
• ea025414101ex99-1_ascentage.htm (EX-99.1) — 138KB
• ea025414101ex99-2_ascentage.htm (EX-99.2) — 696KB
• ea025414101ex99-3_ascentage.htm (EX-99.4) — 87KB
• ex99-2_001.jpg (GRAPHIC) — 18KB
• ex99-2_002.jpg (GRAPHIC) — 199KB
• ex99-2_003.jpg (GRAPHIC) — 174KB
• ex99-2_004.jpg (GRAPHIC) — 186KB
• 0001213900-25-079435.txt ( ) — 1732KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Explanatory Note On August 20, 2025, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued a press release entitled, “Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates”. A copy of the press release is furnished as Exhibit 99.1 to this Report. On August 21, 2025, Ascentage Pharma Group International posted an announcement on the Hong Kong Stock Exchange entitled, “Announcement of Unaudited Interim Results for the Six Months Ended June 30, 2025”. A copy of the announcement is furnished as Exhibit 99.2 to this Report. Approval of New Form of Indemnification Agreement and Interest Payments As previously disclosed, on July 17, 2025, the Company closed an offshore placement and top-up subscription of new shares pursuant to which Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”), offered and sold 22 million ordinary shares, par value US$0.0001 per share, of the Company at a price of HKD68.60 per share and 22 million new ordinary shares were issued to the Vendor at a price of HKD68.60, resulting in net proceeds to the Company of approximately HKD1,492 million (approximately US$190.1 million based on an exchange rate of 1 USD to 7.85 HKD). Given the advantages realized by the Company through the use of the above top-up placement, and the Company’s January 2023 top-up placement, the Company’s Board considered and approved certain amendments to the indemnification agreement for its directors and officers (“Indemnification Agreement”). The Indemnification Agreement amends the existing form of indemnification agreement, filed as Exhibit 4.1 to the Company’s most recent annual report on Form 20-F, to provide for indemnification of affiliates of an indemnitee for any action or inaction taken by the indemnitee in the role of an officer or director of the Company, or by such affiliates in their capacity of a shareholder of the Company, for actions taken at the request of the Company (each such affiliate and indemnitee, an “Indemnified Person”) and approved, as necessary, by the Company’s Board. There were no other substantive changes made to the existing form of indemnification agreement. In addition, considering that the underlying structure of these top-up placements represents a de-facto share-loan arrangement, whereby Indemnified Persons loaned ordinary shares for specific period of days, respectively, the Board considered and approved the payment of up to $600,000 in interest payments to those Indemnified Persons that enabled the successful completion of those top-up placements. The foregoing description of the Indemnification Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of indemnification agreement, which is filed as Exhibit 99.3 to this report on Form 6-K and is incorporated herein by reference. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press release dated August 20, 2025 99.2 Announcement dated August 21, 2025 99.3 Indemnification Agreement 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: August 21, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR